Health Monitor Liechtenstein: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Liechtenstein.

Press releases published on September 2, 2026

Sep. 2, 2026

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire

Sep. 2, 2026

BioRestorative Therapies Announces Reverse Stock Split

Indeterminate GlobeNewswire

Sep. 2, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Supernus Pharmaceuticals to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Vireo Growth Announces Conference Attendance for September 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

Indeterminate GlobeNewswire

Sep. 2, 2026

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

Indeterminate GlobeNewswire

Sep. 2, 2026

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Indeterminate GlobeNewswire

Sep. 2, 2026

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

Indeterminate GlobeNewswire

Sep. 2, 2026

Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique Complet

Indeterminate GlobeNewswire

Sep. 2, 2026

Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH

Indeterminate GlobeNewswire

Sep. 2, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Surrozen to Present at Upcoming Healthcare Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Indeterminate GlobeNewswire